This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Tocris Bioscience
product type :
chemical
product name :
CGK 733
catalog :
2639/10
quantity :
10 mg (also 50 mg)
price :
183 USD
citations: 3
Reference |
---|
Labay E, Efimova E, Quarshie B, Golden D, Weichselbaum R, Kron S. Ionizing radiation-induced foci persistence screen to discover enhancers of accelerated senescence. Int J High Throughput Screen. 2011;2:1-13 pubmed
|
product information
brand :
Tocris, a Bio-Techne brand
catalog number base :
2639
SKU :
2639/10
product name :
CGK 733
description :
Induces apoptosis in prematurely senescent cells
target :
ATM and ATR Kinase Inhibitors
unit size :
10 mg (also 50 mg)
category :
Small Molecules
purity :
98%
storage :
Store at +4°C
observed molecular weight :
555.84
url print :
?utm_source=biocompare&utm_medium=referral&utm_campaign=product&utm_term=smallmolecules
details of functionality :
Originally defined as a selective inhibitor of ATR and ATM kinases. Induces cell death in prematurely senescent breast cancer cells. Decreases p21CIP1 levels in premature senescent MCF-7 and HCT-116 cells; also exhibits antiproliferative activity in a range of cancer cell lines. Blocks camptothecin -induced p53 phosphorylation and protects cells from camptothecin-induced apoptosis.
product keywords :
CGK733 p21 antiproliferative p53 Other Apoptosis 2639,
extended description :
Induces apoptosis in prematurely senescent cells
chemical name text :
-Phenyl-N-[2,2,2-trichloro-1-[[[(4-fluoro-3-nitrophenyl)amino]thioxomethyl]amino]ethyl]benzeneacetamide
formula :
C23H18Cl3FN4O3S
formula text :
C23H18Cl3FN4O3S
cas num :
905973-89-9
USD :
203
USD 2025 :
183 USD
product details :
Induces apoptosis in prematurely senescent cells
company information

Tocris Bioscience
The Watkins Building
Atlantic Road
Avonmouth, Bristol
BS11 9QD
Atlantic Road
Avonmouth, Bristol
BS11 9QD
info@bio-techne.com
https://www.tocris.com800-343-7475
headquarters: UK
questions and comments